Kygevvi (doxecitine and doxribtimine) for thymidine kinase 2 deficiency: a turning point for an ultra-rare mitochondrial disorder.
Saved in:
| Title: | Kygevvi (doxecitine and doxribtimine) for thymidine kinase 2 deficiency: a turning point for an ultra-rare mitochondrial disorder. |
|---|---|
| Authors: | Bob-Ume, Nwamaka Chidera1,2 (AUTHOR), Omotoso, Esther Oluwafunmilayo3 (AUTHOR) omotosoesther12@yahoo.com, Bob-Ume, Chizoba Sandra4 (AUTHOR), Akpabio, JohnPaul Steve2,5 (AUTHOR), Akpabio, Stella Steve5 (AUTHOR), Bob-Ume, Kosisochukwu Chinenye2 (AUTHOR), Bob-Ume, Ebelechukwu Isioma2 (AUTHOR), Ebenezer, PraiseGod Monday5 (AUTHOR), Lot, Joseph Uso5 (AUTHOR), Orji, Precious Nmesomachi5 (AUTHOR), Okon, Bernard Dominic5 (AUTHOR), Amaugo, Rita Chinecherem5 (AUTHOR), Bright, Ediomo Joseph5 (AUTHOR), Oladipupo, Abdulhakeem Abdulsalam6 (AUTHOR) |
| Source: | Journal of Rare Diseases. 6/8/2026, Vol. 5 Issue 1, p1-7. 7p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
